Effect of therapeutic versus prophylactic anticoagulation therapy on clinical outcomes in COVID-19 patients: a systematic review with an updated meta-analysis

[1] Ortega-Paz L(2021)Coronavirus disease 2019-associated thrombosis and coagulopathy: review of the pathophysiological characteristics and implications for antithrombotic management J Am Heart Assoc 10 e019650-632

[2] Capodanno D(2021)Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19 Ann Intern Med 174 622-128

[3] Montalescot G(2020)Pulmonary vascular Endothelialitis, thrombosis, and angiogenesis in Covid-19 N Engl J Med 383 120-500

[4] Angiolillo DJ(2020)COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection Blood 136 489-1480

[5] Al-Samkari H(2021)Pulmonary thrombosis and thromboembolism in COVID-19 Chest 160 1471-174

[6] Gupta S(2021)A systematic review and a Meta-analysis comparing prophylactic and therapeutic low molecular weight heparins for mortality reduction in 32,688 COVID-19 patients Front Pharmacol 12 698008-151

[7] Leaf RK(2021)Association of anticoagulation dose and survival in hospitalized COVID-19 patients: a retrospective propensity score-weighted analysis Eur J Haematol 106 165-1826

[8] Wang W(1975)Actions and interactions of antithrombin and heparin N Engl J Med 292 146-2234

[9] Rosovsky RP(2020)Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19 J Am Coll Cardiol 76 1815-789

[10] Brenner SK(2021)Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multi-center, open-label, randomized controlled trial J Thromb Haemost 19 2225-366

[1] Ortega-Paz L(2021)Coronavirus disease 2019-associated thrombosis and coagulopathy: review of the pathophysiological characteristics and implications for antithrombotic management J Am Heart Assoc 10 e019650-632

[2] Capodanno D(2021)Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19 Ann Intern Med 174 622-128

[3] Montalescot G(2020)Pulmonary vascular Endothelialitis, thrombosis, and angiogenesis in Covid-19 N Engl J Med 383 120-500

[4] Angiolillo DJ(2020)COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection Blood 136 489-1480

[5] Al-Samkari H(2021)Pulmonary thrombosis and thromboembolism in COVID-19 Chest 160 1471-174

[6] Gupta S(2021)A systematic review and a Meta-analysis comparing prophylactic and therapeutic low molecular weight heparins for mortality reduction in 32,688 COVID-19 patients Front Pharmacol 12 698008-151

[7] Leaf RK(2021)Association of anticoagulation dose and survival in hospitalized COVID-19 patients: a retrospective propensity score-weighted analysis Eur J Haematol 106 165-1826

[8] Wang W(1975)Actions and interactions of antithrombin and heparin N Engl J Med 292 146-2234

[9] Rosovsky RP(2020)Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19 J Am Coll Cardiol 76 1815-789

[10] Brenner SK(2021)Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multi-center, open-label, randomized controlled trial J Thromb Haemost 19 2225-366